{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:17:57Z","timestamp":1789676277071,"version":"4.0.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T00:00:00Z","timestamp":1521590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00228-018-2444-2","type":"journal-article","created":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T07:36:02Z","timestamp":1521617762000},"page":"793-803","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy"],"prefix":"10.1007","volume":"74","author":[{"given":"Christelle","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Chhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Dulac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Jullien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,21]]},"reference":[{"key":"2444_CR1","first-page":"435","volume":"18","author":"H Meunier","year":"1963","unstructured":"Meunier H, Carraz G, Meunier Y, Eymard P, Aimard M (1963) Propri\u00e9t\u00e9s pharmacodynamiques de l\u2019acide N-dipropylac\u00e9tique. Therapie 18:435\u2013438","journal-title":"Therapie"},{"key":"2444_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1527-3458.2003.tb00249.x","volume":"9","author":"CU Johannessen","year":"2003","unstructured":"Johannessen CU, Johannessen SI (2003) Valproate: past, present, and future. CNS Drug Rev 9:199\u2013216","journal-title":"CNS Drug Rev"},{"key":"2444_CR3","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","volume":"16","author":"E Perucca","year":"2002","unstructured":"Perucca E (2002) Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16:695\u2013714","journal-title":"CNS Drugs"},{"key":"2444_CR4","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1515\/CCLM.2004.245","volume":"42","author":"HM Neels","year":"2004","unstructured":"Neels HM, Sierens AC, Naelaerts K, Scharpe SL, Hatfield GM, Lambert WE (2004) Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 42:1228\u20131255","journal-title":"Clin Chem Lab Med"},{"key":"2444_CR5","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E (2008) Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49:1239\u20131276","journal-title":"Epilepsia"},{"key":"2444_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/BF00315328","volume":"238","author":"L Herngren","year":"1991","unstructured":"Herngren L, Lundberg B (1991) Pharmacokinetics of total and free valproic acid during monotherapy in infants. J Neurol 238:315\u2013319","journal-title":"J Neurol"},{"key":"2444_CR7","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1177\/00912709922011728","volume":"39","author":"Y Kodama","year":"1999","unstructured":"Kodama Y, Kodama H, Kuranari M, Tsutsumi K, Ono S, Fujimura A (1999) No effect of gender or age on binding characteristics of valproic acid to serum proteins in pediatric patients with epilepsy. J Clin Pharmacol 39:1070\u20131076","journal-title":"J Clin Pharmacol"},{"key":"2444_CR8","unstructured":"ANSM (2013) Micropakine L.P - R\u00e9sum\u00e9 des caract\u00e9ristiques du produit (SCP) Available at: \n                    http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0224686.htm\n                    \n                  . Accessed 3 May 2017"},{"key":"2444_CR9","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/cpt1977216736","volume":"21","author":"U Klotz","year":"1977","unstructured":"Klotz U, Antonin KH (1977) Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther 21:736\u2013743","journal-title":"Clin Pharmacol Ther"},{"key":"2444_CR10","unstructured":"Medicines.org.uk (2015) Epilim Chronosphere - Summary of product characteristics (SPC) Available at: \n                    https:\/\/www.medicines.org.uk\/emc\/files\/pil.3988.pdf\n                    \n                  . Accessed 3 May 2017"},{"key":"2444_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/ana.410140107","volume":"14","author":"DM Turnbull","year":"1983","unstructured":"Turnbull DM, Rawlins MD, Weightman D, Chadwick DW (1983) Plasma concentrations of sodium valproate: their clinical value. Ann Neurol 14:38\u201342","journal-title":"Ann Neurol"},{"key":"2444_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.4155\/tde.11.19","volume":"2","author":"JA Y\u00e1\u00f1ez","year":"2012","unstructured":"Y\u00e1\u00f1ez JA, Remsberg CM, Sayre CL, Forrest ML, Davies NM (2012) Flip-flop pharmacokinetics\u2014delivering a reversal of disposition: challenges and opportunities during drug development. Ther Deliv 2:643\u2013672","journal-title":"Ther Deliv"},{"key":"2444_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40262-014-0212-8","volume":"54","author":"J Ding","year":"2015","unstructured":"Ding J, Wang Y, Lin W, Wang C, Zhao L, Li X, Zhao Z, Miao L, Jiao Z (2015) A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy\u00a0: a non-linear pharmacokinetic model based on protein-binding saturation. Clin Pharmacokinet 54:305\u2013317","journal-title":"Clin Pharmacokinet"},{"key":"2444_CR14","unstructured":"Holford N. Protein binding model 2011. \n                    http:\/\/www.cognigencorp.com\/nonmem\/current\/2011-May\/2497.html\n                    \n                  . Accessed 20 Jun 2017"},{"key":"2444_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1365-2710.2008.00885.x","volume":"33","author":"S Ueshima","year":"2008","unstructured":"Ueshima S, Aiba T, Makita T, Nishihara S, Kitamura Y, Kurosaki Y, Kawasaki H, Sendo T, Ohtsuka Y, Gomita Y (2008) Characterization of non-linear relationship between total and unbound serum concentrations of valproic acid in epileptic children. J Clin Pharm Ther 33:31\u201338","journal-title":"J Clin Pharm Ther"},{"key":"2444_CR16","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/(SICI)1097-0258(19960715)15:13<1325::AID-SIM233>3.0.CO;2-K","volume":"15","author":"BJ Bailey","year":"1996","unstructured":"Bailey BJ, Briars GL (1996) Estimating the surface area of the human body. Stat Med 15:1325\u20131332","journal-title":"Stat Med"},{"key":"2444_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NHG (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303\u2013332","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2444_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2165\/00003088-200847040-00002","volume":"47","author":"M Tod","year":"2008","unstructured":"Tod M, Jullien V, Pons G (2008) Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 47:231\u2013243","journal-title":"Clin Pharmacokinet"},{"key":"2444_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","volume":"90","author":"E Comets","year":"2008","unstructured":"Comets E, Brendel K, Mentr\u00e9 F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Prog Biomed 90:154\u2013166","journal-title":"Comput Methods Prog Biomed"},{"key":"2444_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143\u2013151","journal-title":"AAPS J"},{"key":"2444_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0169-2607(98)00098-4","volume":"59","author":"J Parke","year":"1999","unstructured":"Parke J, Holford NHG, Charles BG (1999) A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Prog Biomed 59:19\u201329","journal-title":"Comput Methods Prog Biomed"},{"key":"2444_CR22","unstructured":"Dhillon S, Gill K (2006) Basic pharmacokinetics. In: Dhillon S, Kostrzewski A (eds) Clinical Pharmacokinetics, 1st edn. Pharmaceutical Press, p 1\u201344"},{"key":"2444_CR23","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/jps.23574","volume":"102","author":"N Holford","year":"2013","unstructured":"Holford N, Heo Y-A, Anderson B (2013) A pharmacokinetic standard for babies and adults. J Pharm Sci 102:2941\u20132952","journal-title":"J Pharm Sci"},{"key":"2444_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1592\/phco.25.1.35.55626","volume":"25","author":"O Dulac","year":"2005","unstructured":"Dulac O, Alvarez J (2005) Bioequivalence of a new sustained-release formulation of sodium valproate , valproate modified-release granules , compared with existing sustained-release formulations after once- or twice-daily administration. Pharmacotherapy 25:35\u201341","journal-title":"Pharmacotherapy"},{"key":"2444_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/01.mjt.0000155113.89092.58","volume":"13","author":"PDN Ayudhya","year":"2006","unstructured":"Ayudhya PDN, Suwanmanee J, Visudtibhan A (2006) Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children. Am J Ther 13:211\u2013217","journal-title":"Am J Ther"},{"key":"2444_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/clpt.1993.5","volume":"53","author":"JC Cloyd","year":"1993","unstructured":"Cloyd JC, Fisher JH, Kriel RL, Kraus DM (1993) Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin Pharmacol Ther 53:22\u201329","journal-title":"Clin Pharmacol Ther"},{"key":"2444_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/BF00561679","volume":"17","author":"GJ Schapel","year":"1980","unstructured":"Schapel GJ, Beran RG, Doecke CJ, O\u2019Reilly WJ, Reece PA, Rischbieth RHC et al (1980) Pharmacokinetics of sodium valproate in epileptic patients\u00a0: prediction of maintenance dosage by single-dose study. Eur J Clin Pharmacol 17:71\u201377","journal-title":"Eur J Clin Pharmacol"},{"key":"2444_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1528-1157.1982.tb05063.x","volume":"23","author":"V Nitsche","year":"1982","unstructured":"Nitsche V, Mascher H (1982) The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers. Epilepsia 23:153\u2013162","journal-title":"Epilepsia"},{"key":"2444_CR29","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1111\/j.1745-7254.2007.00704.x","volume":"28","author":"D Jiang","year":"2007","unstructured":"Jiang D, Wang L, Wang Y, Li L, Lu W, Bai X (2007) Population pharmacokinetics of valproate in Chinese children with epilepsy. Acta Pharmacol Sin 28:1677\u20131684","journal-title":"Acta Pharmacol Sin"},{"key":"2444_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40263-015-0304-5","volume":"30","author":"AM Cook","year":"2016","unstructured":"Cook AM, Zafar MS, Mathias S, Stewart AM, Albuja AC, Bensalem-Owen M, Kapoor S, Baumann RJ (2016) Pharmacokinetics and clinical utility of valproic acid administered via continuous infusion. CNS Drugs 30:71\u201377","journal-title":"CNS Drugs"},{"key":"2444_CR31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/j.1552-4604.1985.tb02836.x","volume":"25","author":"K Hall","year":"1985","unstructured":"Hall K, Otten N, Johnston B, Irvine-Meel J, Leroux M, Seshia S (1985) A multivariable analysis of factors governing the steady-state pharmacokinetics of valproic acid in 52 young epileptics. J Clin Pharmacol 25:261\u2013268","journal-title":"J Clin Pharmacol"},{"key":"2444_CR32","first-page":"1","volume":"3","author":"ML Buck","year":"1997","unstructured":"Buck ML (1997) Valproic acid in the treatment of pediatric seizures. Pediatr Pharmacother 3:1\u20134","journal-title":"Pediatr Pharmacother"},{"key":"2444_CR33","unstructured":"Shen DD, Levy RH (1999) Valproate. In: Eadie MJ, Vajda FJE (eds). Handb. Exp. Pharmacol. Antiepileptic Drugs, Pharmacol. Ther. Springer, p 359\u2013374"},{"key":"2444_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1067\/mcp.2002.121829","volume":"71","author":"LZ Benet","year":"2002","unstructured":"Benet LZ, Hoener B (2002) Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115\u2013121","journal-title":"Clin Pharmacol Ther"},{"key":"2444_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1046\/j.1365-2710.1999.00202.x","volume":"24","author":"B Blanco-Serrano","year":"1999","unstructured":"Blanco-Serrano B, Garc\u00eda-S\u00e1nchez MJ, Otero MJ, Buelga DS, Serrano J, Dom\u00ednguez-Gil A (1999) Valproate population pharmacokinetics in children. J Clin Pharm Ther 24:73\u201380. \n                    https:\/\/doi.org\/10.1046\/j.1365-2710.1999.00202.x","journal-title":"J Clin Pharm Ther"},{"key":"2444_CR36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/(SICI)1099-081X(199907)20:5<233::AID-BDD179>3.0.CO;2-5","volume":"20","author":"B Blanco-serrano","year":"1999","unstructured":"Blanco-serrano B, Otero MJ, Santos-buelga D, Garc\u00eda S\u00e1nchez MJ, Serrano J, Dom\u00ednguez-Gil A (1999) Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. Biopharm Drug Dispos 20:233\u2013240","journal-title":"Biopharm Drug Dispos"},{"key":"2444_CR37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/bdd.636","volume":"29","author":"T Correa","year":"2008","unstructured":"Correa T, Rodriguez I, Romano S (2008) Population pharmacokinetics of valproate in Mexican children with epilepsy. Biopharm Drug Dispos 29:511\u2013520","journal-title":"Biopharm Drug Dispos"},{"key":"2444_CR38","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00228-003-0699-7","volume":"59","author":"ESEL Desoky","year":"2004","unstructured":"Desoky ESEL, Fuseau E, Amry SED, Cosson V (2004) Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients. Eur J Clin Pharmacol 59:783\u2013790. \n                    https:\/\/doi.org\/10.1007\/s00228-003-0699-7","journal-title":"Eur J Clin Pharmacol"},{"key":"2444_CR39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/FTD.0000000000000100","volume":"37","author":"W Lin","year":"2015","unstructured":"Lin W, Jiao Z, Wang C, Wang H, Ma C, Huang P, Guo XZ, Liu YW (2015) Population pharmacokinetics of valproic acid in adult Chinese epileptic patients and its application in an individualized dosage regimen. Ther Drug Monit 37:76\u201383","journal-title":"Ther Drug Monit"},{"key":"2444_CR40","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s10928-005-0083-6","volume":"32","author":"JE Ahn","year":"2005","unstructured":"Ahn JE, Birnbaum AK, Brundage RC (2005) Inherent correlation between dose and clearance in therapeutic drug monitoring settings\u00a0: possible misinterpretation in population pharmacokinetic analyses. J Pharmacokinet Pharmacodyn 32:703\u2013718","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2444_CR41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/JCP.0b013e318203b405","volume":"31","author":"T Sriboonruang","year":"2011","unstructured":"Sriboonruang T, Panomvana D, Chamchitchun S, Silpakit O (2011) The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients. J Clin Psychopharmacol 31:115\u2013119. \n                    https:\/\/doi.org\/10.1097\/JCP.0b013e318203b405","journal-title":"J Clin Psychopharmacol"},{"key":"2444_CR42","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/FTD.0000000000000405","volume":"39","author":"E Wallenburg","year":"2017","unstructured":"Wallenburg E, Klok B, de Jong K, de Maat M, Van EN, Stalpers-Konijnenburg S et al (2017) Monitoring protein-unbound valproic acid serum concentrations in clinical practice. Ther Drug Monit 39:269\u2013272","journal-title":"Ther Drug Monit"},{"key":"2444_CR43","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00003088-198815060-00002","volume":"15","author":"G Zaccara","year":"1988","unstructured":"Zaccara G, Messori A, Moroni F (1988) Clinical pharmacokinetics of valproic acid\u20141988. Clin Pharmacokinet 15:367\u2013389","journal-title":"Clin Pharmacokinet"},{"key":"2444_CR44","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology\u2014drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157\u20131167","journal-title":"N Engl J Med"},{"key":"2444_CR45","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S0022-3476(85)80097-4","volume":"106","author":"K Chiba","year":"1985","unstructured":"Chiba K, Suganuma T, Ishizaki T, Iriki T, Shirai Y, Naitoh H, Hori M (1985) Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment. J Pediatr 106:653\u2013658","journal-title":"J Pediatr"},{"key":"2444_CR46","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/088307389701200311","volume":"12","author":"JGW Theis","year":"1997","unstructured":"Theis JGW, Koren G, Daneman R, Sherwin AL, Menzano E, Cortez M, Hwang P (1997) Interactions of clobazam with conventional antiepileptics in children. J Child Neurol 12:208\u2013213","journal-title":"J Child Neurol"},{"key":"2444_CR47","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/clpt.1990.144","volume":"48","author":"RH Levy","year":"1990","unstructured":"Levy RH, Rettenmeier AW, Anderson GD, Wilensky AJ, Friel PN, Baillie TA, Acheampong A, Tor J, Guyot M, Loiseau P (1990) Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatoxic metabolite of valproic acid. Clin Pharmacol Ther 48:225\u2013235","journal-title":"Clin Pharmacol Ther"},{"key":"2444_CR48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.eplepsyres.2016.12.014","volume":"130","author":"T Jogamoto","year":"2017","unstructured":"Jogamoto T, Yamamoto Y, Fukuda M, Suzuki Y, Imai K, Takahashi Y, Inoue Y, Ohtsuka Y (2017) Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy. Epilepsy Res 130:7\u201312","journal-title":"Epilepsy Res"},{"key":"2444_CR49","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/00007691-199208000-00002","volume":"14","author":"S Sennoune","year":"1990","unstructured":"Sennoune S, Mesdjian E, Bonneton J, Genton P, Dravet C, Roger J (1990) Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Ther Drug Monit 14:269\u2013274","journal-title":"Ther Drug Monit"},{"key":"2444_CR50","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/j.1875-9114.2012.01028.x","volume":"32","author":"M Walzer","year":"2012","unstructured":"Walzer M, Bekersky I, Blum RA, Tolbert D (2012) Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy 32:340\u2013353","journal-title":"Pharmacotherapy"},{"key":"2444_CR51","first-page":"119","volume":"10","author":"CJ Landmark","year":"2010","unstructured":"Landmark CJ, Patsalos PN (2010) Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev 10:119\u2013140","journal-title":"Expert Rev"},{"key":"2444_CR52","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1528-1157.1993.tb02416.x","volume":"34","author":"JR Farwell","year":"1993","unstructured":"Farwell JR, Anderson GD, Kerr BM, Tor JA, Levy IH (1993) Stiripentol in atypical absence seizures in children: an open trial. Epilepsia 34:305\u2013311","journal-title":"Epilepsia"},{"key":"2444_CR53","first-page":"20","volume-title":"Pediatr. epilepsy case stud. From infancy child. Through Adolesc","author":"GD Anderson","year":"2008","unstructured":"Anderson GD, Rho JM (2008) AEDs Eliminated by Mixed CYP, UGT, and other metabolic pathways. In: Chapman K, Rho JM (eds) Pediatr. epilepsy case stud. From infancy child. Through Adolesc. CRC Press, Boca Raton, pp 20\u201321"},{"key":"2444_CR54","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/j.1552-4604.1997.tb04301.x","volume":"37","author":"E Yukawa","year":"1997","unstructured":"Yukawa E, To H, Ohdo S, Higuchi S, Aoyama T (1997) Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of interaction and patient characteristics. J Clin Pharmacol 37:1160\u20131167","journal-title":"J Clin Pharmacol"},{"key":"2444_CR55","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1365-2710.2003.00538.x","volume":"29","author":"IB Bondareva","year":"2004","unstructured":"Bondareva IB, Jelliffe RW, Sokolov AV, Tischenkova IF (2004) Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data\u00a0: implications for dosage. J Clin Pharm Ther 29:105\u2013120","journal-title":"J Clin Pharm Ther"},{"key":"2444_CR56","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bcp.12267","volume":"79","author":"HK Batchelor","year":"2013","unstructured":"Batchelor HK, Marriott JF (2013) Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol 79:395\u2013404","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"2444_CR57","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa0902014","volume":"362","author":"TA Glauser","year":"2010","unstructured":"Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC, Childhood Absence Epilepsy Study Group (2010) Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 362(9):790\u2013799","journal-title":"N Engl J Med"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-2444-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2444-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2444-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T20:11:31Z","timestamp":1553112691000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-2444-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,21]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["2444"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-2444-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,21]]},"assertion":[{"value":"6 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"CR reports personal fees from Biocodex, outside the submitted work. CC reports personal fees and non-financial support from Biocodex; personal fees from Brabant, UCB-Pharma, Bial, Zogenix, and Viropharma, outside the submitted work; and declare that she was the PI of the two clinical studies mentioned in the paper. As clinical principal investigator, CC recruited and followed the patients during the studies. That did not influence what is written in the submitted work. VJ, SC, ER, GP, and OD have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}